Clinical Trials Logo

Mountain Sickness clinical trials

View clinical trials related to Mountain Sickness.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04075565 Completed - Hypoxia Clinical Trials

The Psychophysiological Effect of Simulated and Terrestrial Altitude

Hypoxia
Start date: June 24, 2019
Phase: N/A
Study type: Interventional

The aim of this study is to compare the psychophysiological effects of terrestrial altitude with a normobaric, hypoxic situation.

NCT ID: NCT02463357 Completed - Mountain Sickness Clinical Trials

Three New Ideas to Protect Special Forces From the Stress of High Altitude

Start date: August 2015
Phase: Phase 4
Study type: Interventional

Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance and endurance exercise capacity are impaired. Therefore, the goal of this research is to identify effective pharmacological agents that will help reduce the symptoms of AMS and improve physical and cognitive performance at high altitude. The investigators will study the efficacy of the dietary supplement, quercetin, the drugs nifedipine (extended release) and methazolamide taken together, the drug metformin, and the drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.

NCT ID: NCT01587027 Completed - Mountain Sickness Clinical Trials

Safety Evaluation of Aminophylline and Methazolamide

Start date: December 2011
Phase: Phase 1
Study type: Interventional

This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.

NCT ID: NCT01187108 Completed - Mountain Sickness Clinical Trials

Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru

CoCMS
Start date: June 2013
Phase: Phase 1/Phase 2
Study type: Interventional

Chronic mountain sickness is characterized by excessive red blood cell production which causes sludging of the vascular system. This high viscosity blood causes heart failure, cognitive dysfunction, and strokes. The investigators hypothesize that cobalt which has been previously been shown to be an environmental pollutant worsens the overproduction of red blood cells. The investigators plan to conduct a 6 week trial in which acetazolamide (already shown to improve chronic mountain sickness) and N-acetylcysteine (a drug that removes cobalt from the blood) are evaluated in their potential to improve chronic mountain sickness.

NCT ID: NCT00952302 Completed - Clinical trials for Pulmonary Hypertension

Study of the Effects of Iron Levels on the Lungs at High Altitude

Start date: October 2008
Phase: N/A
Study type: Interventional

The study hypothesis is that body iron levels are important in determining the increase in lung blood pressure that occurs in response to low oxygen levels. The purpose of this study is to determine whether this is true at high altitude, where oxygen levels are low.